Response: Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.
作者信息
Santi Daniele, Casarini Livio, Alviggi Carlo, Simoni Manuela
机构信息
Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Unit of Endocrinology, Department of Medicine, Endocrinology, Metabolism and Geriatrics, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
出版信息
Front Endocrinol (Lausanne). 2018 Mar 23;9:113. doi: 10.3389/fendo.2018.00113. eCollection 2018.
Abstract
摘要
相似文献
1
Response: Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.回应：评论：在“个性化”医学时代，单独使用促卵泡激素（FSH）、FSH+促黄体生成素、人绝经期促性腺激素或FSH+人绒毛膜促性腺激素对辅助生殖技术结局的疗效：一项荟萃分析。
Front Endocrinol (Lausanne). 2018 Mar 23;9:113. doi: 10.3389/fendo.2018.00113. eCollection 2018.
2
Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.在“个性化”医学时代，单独使用促卵泡激素（FSH）、FSH + 促黄体生成素、人绝经期促性腺激素或FSH + 人绒毛膜促性腺激素对辅助生殖技术结局的疗效：一项荟萃分析。
Front Endocrinol (Lausanne). 2017 Jun 1;8:114. doi: 10.3389/fendo.2017.00114. eCollection 2017.
3
Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.评论：在“个性化”医学时代，单独使用促卵泡激素（FSH）、FSH + 促黄体生成素、人绝经期促性腺激素或FSH + 人绒毛膜促性腺激素对辅助生殖技术结局的疗效：一项荟萃分析。
Front Endocrinol (Lausanne). 2017 Oct 5;8:264. doi: 10.3389/fendo.2017.00264. eCollection 2017.
4
Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.重组卵泡刺激素和重组促黄体生成素联合 GnRH 拮抗剂方案与单独使用重组卵泡刺激素方案在年龄≥35 岁患者卵巢刺激中的随机对照研究。
Hum Reprod. 2015 May;30(5):1188-95. doi: 10.1093/humrep/dev038. Epub 2015 Mar 3.
5
Ovarian stimulation protocols in assisted reproductive technology: an update.辅助生殖技术中的卵巢刺激方案：最新进展
Expert Rev Endocrinol Metab. 2012 May;7(3):319-330. doi: 10.1586/eem.12.18.
6
[Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].国产高纯度尿促卵泡素对控制性卵巢刺激中体外受精-胚胎移植结局的影响
Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):838-42.
7
Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.在微刺激周期中，于卵泡中期使用重组促卵泡激素联合重组促黄体生成素或低剂量重组人绒毛膜促性腺激素进行促排卵对卵巢低反应者的临床效果。
Fertil Steril. 2007 Sep;88(3):665-9. doi: 10.1016/j.fertnstert.2006.11.150. Epub 2007 Feb 12.
8
A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.比较使用重组促黄体生成激素（LH）或作为 LH 类似物的人绒毛膜促性腺激素刺激的体外受精周期在卵巢储备良好或较差的受试者中的结局：回顾性分析。
Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:70-3. doi: 10.1016/j.ejogrb.2013.10.027. Epub 2013 Nov 5.
9
Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.人绝经期促性腺激素和促卵泡生成素与促性腺激素释放激素激动剂脱敏用于体外受精中控制性卵巢过度刺激的比较。
Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jun;55(6):452-6.
10
引用本文的文献
1
Exploring the Impact of Controlled Ovarian Stimulation and Non-Invasive Oocyte Assessment in ART Treatments.探索控制性卵巢刺激和无创性卵母细胞评估在辅助生殖技术治疗中的影响。
Life (Basel). 2023 Sep 29;13(10):1989. doi: 10.3390/life13101989.
2
Treatment modalities for poor ovarian responders.卵巢低反应者的治疗方式。
Ther Adv Reprod Health. 2023 Jan 24;17:26334941221147464. doi: 10.1177/26334941221147464. eCollection 2023 Jan-Dec.
3
An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria.一项针对4828个体外受精周期的观察性回顾性队列试验，根据POSEIDON标准评估不同低预后患者。
Front Endocrinol (Lausanne). 2019 May 8;10:282. doi: 10.3389/fendo.2019.00282. eCollection 2019.
4
Comparison of recombinant and urinary follicle-stimulating hormones over 2000 gonadotropin-releasing hormone antagonist cycles: a retrospective study.2000 多个促性腺激素释放激素拮抗剂周期中重组和尿源性促卵泡激素的比较：一项回顾性研究。
Sci Rep. 2019 Mar 29;9(1):5329. doi: 10.1038/s41598-019-41846-2.
本文引用的文献
1
Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.评论：在“个性化”医学时代，单独使用促卵泡激素（FSH）、FSH + 促黄体生成素、人绝经期促性腺激素或FSH + 人绒毛膜促性腺激素对辅助生殖技术结局的疗效：一项荟萃分析。
Front Endocrinol (Lausanne). 2017 Oct 5;8:264. doi: 10.3389/fendo.2017.00264. eCollection 2017.
2
The high responder: a review of pathophysiology and outcomes during IVF treatment.高反应者：体外受精治疗期间的病理生理学及结局综述
Hum Fertil (Camb). 2017 Sep;20(3):155-167. doi: 10.1080/14647273.2017.1293851. Epub 2017 Feb 28.
3
Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.在“个性化”医学时代，单独使用促卵泡激素（FSH）、FSH + 促黄体生成素、人绝经期促性腺激素或FSH + 人绒毛膜促性腺激素对辅助生殖技术结局的疗效：一项荟萃分析。
Front Endocrinol (Lausanne). 2017 Jun 1;8:114. doi: 10.3389/fendo.2017.00114. eCollection 2017.
4
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.重组促黄体生成素（rLH）和重组促卵泡生成素（rFSH）用于体外受精/卵胞浆内单精子注射周期中的卵巢刺激。
Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3.
5
Estrogen Modulates Specific Life and Death Signals Induced by LH and hCG in Human Primary Granulosa Cells In Vitro.雌激素在体外对人原代颗粒细胞中由促黄体生成素和人绒毛膜促性腺激素诱导的特定生死信号进行调节。
Int J Mol Sci. 2017 Apr 28;18(5):926. doi: 10.3390/ijms18050926.
6
Human Luteinizing Hormone and Chorionic Gonadotropin Display Biased Agonism at the LH and LH/CG Receptors.人促黄体生成素和绒促性素在 LH 和 LH/CG 受体上表现出偏向激动作用。
Sci Rep. 2017 Apr 19;7(1):940. doi: 10.1038/s41598-017-01078-8.
7
The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome.辅助生殖技术中“低预后患者”的新型波塞冬分层及其成功结局的提议标志物。
F1000Res. 2016 Dec 23;5:2911. doi: 10.12688/f1000research.10382.1. eCollection 2016.
8
Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro.人促黄体生成素（LH）和人绒毛膜促性腺激素（hCG）对早期信号通路的刺激方式不同，但在体外可使小鼠睾丸间质细胞合成等量的睾酮。
Reprod Biol Endocrinol. 2017 Jan 5;15(1):2. doi: 10.1186/s12958-016-0224-3.
9
Identification and description of controlled clinical trials published in Spanish Gynaecology and Obstetrics journals and risk of bias assessment of trials on assisted reproductive techniques.西班牙妇产科杂志发表的对照临床试验的识别与描述以及辅助生殖技术试验的偏倚风险评估
Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:5-11. doi: 10.1016/j.ejogrb.2016.04.039. Epub 2016 Apr 30.
10
A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept.卵巢刺激低反应者的一种新的更详细分层：从卵巢反应不良到低预后概念。
Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26.
Zotero 插件